MEDP insider ownership: who sold, why, and what they still hold

What stands out

Nine insiders sold $454M with no disclosed plan: August Troendle ($358M), Susan Burwig ($28.8M) and Jesse Geiger ($28.3M), plus 6 more. The filings don't state a reason.August Troendle: largest such sale, Nov 24, 2025 · Susan Burwig: largest such sale, Nov 24, 2025 · Jesse Geiger: largest such sale, Mar 17, 2026

Selling rose in the last 90 days but the year remains well below the 5-year average: officers and directors sold 337K shares, against an average of 145K per 90 days earlier in the period. Most of it was August Troendle (308K shares in the last 90 days) and Susan Burwig (7.5K shares in the last 90 days); 0% of these sales were under disclosed plans.August Troendle: largest recent sale, Sep 22, 2026 · Susan Burwig: largest recent sale, Jul 28, 2026

A share of stake is shown for 0 of the 9 officers and directors who sold. 12 are left out

Left out: August Troendle, Susan Burwig, Jesse Geiger, Brian Carley, Stephen Ewald, Cornelius McCarthy III, Kevin Brady, Fred Davenport Jr., Robert Kraft, Brad Hansman, Femida Gwadry-Sridhar and Dani Zander (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

August Troendle

President & CEO, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$358MNo plan disclosed

Jesse Geiger

President

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$41.1M31% planned 69% no plan disclosed

Susan Burwig

Exec. VP, Operations

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$28.8MNo plan disclosed

Stephen Ewald

General Counsel & Corp. Secy.

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$16.5MNo plan disclosed

Fred Davenport Jr.

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$7.9MNo plan disclosed

All 9 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 30, 2026August Troendle sold 22K shares ($13.7M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	21,966	$625.47	n/a	n/a	Sep 30, 2026	Oct 1, 2026

Sep 29, 2026August Troendle sold 27K shares ($16.6M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	26,701	$621.02	n/a	n/a	Sep 29, 2026	Oct 1, 2026

Sep 28, 2026August Troendle sold 2.4K shares ($1.5M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	2,410	$620.07	n/a	n/a	Sep 28, 2026	Sep 29, 2026

Sep 25, 2026August Troendle sold 154 shares ($96K) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	154	$620.60	n/a	n/a	Sep 25, 2026	Sep 29, 2026

Sep 24, 2026August Troendle sold 28K shares ($17.3M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	27,833	$621.33	n/a	n/a	Sep 24, 2026	Sep 25, 2026

Show all 11 events

Sep 23, 2026August Troendle sold 16K shares ($10.1M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	16,083	$628.64	n/a	n/a	Sep 23, 2026	Sep 25, 2026

Sep 22, 2026August Troendle sold 49K shares ($30.8M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	49,018	$628.11	n/a	n/a	Sep 22, 2026	Sep 23, 2026

Sep 21, 2026August Troendle sold 22K shares ($13.6M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	21,883	$623.29	n/a	n/a	Sep 21, 2026	Sep 23, 2026

Sep 17, 2026August Troendle sold 11K shares ($6.7M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	10,880	$620.40	n/a	n/a	Sep 17, 2026	Sep 21, 2026

Sep 16, 2026August Troendle sold 8.8K shares ($5.4M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	8,770	$621.29	n/a	n/a	Sep 16, 2026	Sep 17, 2026

Sep 15, 2026August Troendle sold 16K shares ($9.9M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
August Troendle President & CEO, Director	15,971	$620.84	n/a	n/a	Sep 15, 2026	Sep 17, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Medpace Holdings, Inc. CEO selling stock?

Yes. August Troendle sold 586K shares ($358M) in the past 12 months, none of it under a trading plan disclosed in the filings.

Why are Medpace Holdings, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 3% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 97% had no disclosed plan. A trading plan schedules sales in advance.

Are any Medpace Holdings, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold9 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
August Troendle President & CEO, Director	$358M 586K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Jesse Geiger President	$41.1M 76K shares	Not confirmed share of stake is being verified. Why	31% under a disclosed plan 69% no plan disclosed
Susan Burwig Exec. VP, Operations	$28.8M 48K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Stephen Ewald General Counsel & Corp. Secy.	$16.5M 32K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Fred Davenport Jr. Director	$7.9M 13K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Robert Kraft Director	$6.2M 10K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Kevin Brady CFO & Treasurer	$3.9M 6.4K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Brian Carley Director	$3.0M 5K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Cornelius McCarthy III Director	$1.2M 1.9K shares	Not confirmed share of stake is being verified. Why	No plan disclosed

The full ownership picture0 of 12 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

August Troendle

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for August Troendle are complete.

President & CEO, Director

n/a

−586K

n/a

Vesting, gifts, unvested awards and holding lines for August Troendle

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for August Troendle are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,000	$377.00	Aug 5, 2031	$12.4M
73,443	$325.73	Mar 6, 2034	$22.0M
20,000	$410.54	Apr 24, 2033	$4.3M

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Susan Burwig

Exec. VP, Operations

n/a

−48K

n/a

Vesting, gifts, unvested awards and holding lines for Susan Burwig

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Susan Burwig are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,028	$166.73	Oct 27, 2026	$2.8M
11,017	$325.73	Mar 6, 2034	$3.3M
10,000	$410.54	Apr 24, 2033	$2.1M

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Jesse Geiger

President

n/a

−76K

n/a

Vesting, gifts, unvested awards and holding lines for Jesse Geiger

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jesse Geiger are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
9,886	$325.73	Mar 6, 2032	$3.0M

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Brian Carley

Director

n/a

−5K

n/a

Vesting, gifts, unvested awards and holding lines for Brian Carley

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brian Carley are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
953	$393.30	May 17, 2031	$221K
1,224	$305.66	May 16, 2032	$391K
1,110	$415.27	May 15, 2033	$233K

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Stephen Ewald

General Counsel & Corp. Secy.

n/a

−32K

n/a

Vesting, gifts, unvested awards and holding lines for Stephen Ewald

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Stephen Ewald are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,591	$325.73	Mar 6, 2032	$2.0M
10,000	$410.54	Apr 24, 2033	$2.1M

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Cornelius McCarthy III

Director

n/a

−1.9K

n/a

Vesting, gifts, unvested awards and holding lines for Cornelius McCarthy III

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Cornelius McCarthy III are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
953	$393.30	May 17, 2031	$221K
1,224	$305.66	May 16, 2032	$391K
1,110	$415.27	May 15, 2033	$233K

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Kevin Brady

CFO & Treasurer

n/a

−6.4K

n/a

Vesting, gifts, unvested awards and holding lines for Kevin Brady

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kevin Brady are complete; balances and unit counts will be added when the check is finished.

−170gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,403	$138.87	Aug 15, 2027	$1.7M
6,591	$325.73	Mar 6, 2032	$2.0M
10,000	$410.54	Apr 24, 2033	$2.1M

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Fred Davenport Jr.

Director

n/a

−13K

n/a

Vesting, gifts, unvested awards and holding lines for Fred Davenport Jr.

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Fred Davenport Jr. are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
953	$393.30	May 17, 2031	$221K
1,224	$305.66	May 16, 2032	$391K
1,110	$415.27	May 15, 2033	$233K

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Robert Kraft

Director

n/a

−10K

n/a

Vesting, gifts, unvested awards and holding lines for Robert Kraft

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Kraft are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
953	$393.30	May 17, 2031	$221K
1,224	$305.66	May 16, 2032	$391K
1,110	$415.27	May 15, 2033	$233K

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Brad Hansman

Exec. VP, Operations

n/a

Vesting, gifts, unvested awards and holding lines for Brad Hansman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brad Hansman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$410.54	Apr 24, 2033	$2.1M

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Femida Gwadry-Sridhar

Director

n/a

Vesting, gifts, unvested awards and holding lines for Femida Gwadry-Sridhar

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Femida Gwadry-Sridhar are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
953	$393.30	May 17, 2031	$221K
1,224	$305.66	May 16, 2032	$391K
1,110	$415.27	May 15, 2033	$233K

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Dani Zander

Director

n/a

Vesting, gifts, unvested awards and holding lines for Dani Zander

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dani Zander are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
824	$407.24	Jul 1, 2031	$180K
1,224	$305.66	May 16, 2032	$391K
1,110	$415.27	May 15, 2033	$233K

Estimate: options held × ($625.47 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Holdings and share of stake for Medpace Holdings, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$467M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $467M across 778,614 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $12.8M · 3%

97%

The lighter segment is sales with no plan disclosed in the filing ($454M), including tax-related sales outside a plan.

No plan disclosed · $454M

Sales with no 10b5-1 plan and no tax reference in the filing. $358M of it is August Troendle. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: August Troendle, Nov 24, 2025

Charitable gifts · 170 shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
August Troendle President & CEO, Director	586K	$358M	0%	77%	Nov 12, 2025 to Sep 30, 2026
Jesse Geiger President	76K	$41.1M	31%	9%	Oct 27, 2025 to Mar 17, 2026
Susan Burwig Exec. VP, Operations	48K	$28.8M	0%	6%	Oct 27, 2025 to Jul 28, 2026
Stephen Ewald General Counsel & Corp. Secy.	32K	$16.5M	0%	4%	Oct 27, 2025 to May 28, 2026
Fred Davenport Jr. Director	13K	$7.9M	0%	2%	Oct 30, 2025 to Aug 19, 2026
Robert Kraft Director	10K	$6.2M	0%	1%	Nov 14, 2025 to Aug 26, 2026
Kevin Brady CFO & Treasurer	6.4K	$3.9M	0%	0.8%	Nov 21, 2025 to Aug 20, 2026
Brian Carley Director	5K	$3.0M	0%	0.7%	Aug 19, 2026 to Aug 19, 2026
Cornelius McCarthy III Director	1.9K	$1.2M	0%	0.2%	Aug 7, 2026 to Aug 11, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$27.7M	$0	$0	$27.7M
Nov 2025	$192M	$12.8M	$0	$179M
Dec 2025	$17.5M	$0	$0	$17.5M
Jan 2026	$0	$0	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$14.4M	$0	$0	$14.4M
Apr 2026	$0	$0	$0	$0
May 2026	$7.4M	$0	$0	$7.4M
Jun 2026	$0	$0	$0	$0
Jul 2026	$8.8M	$0	$0	$8.8M
Aug 2026	$73.8M	$0	$0	$73.8M
Sep 2026	$126M	$0	$0	$126M
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about half of the 5-year average. 9 insiders sold; the average is 6 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	779K	9	$467M
Oct 13, 2025 1 year earlier	168K	8	$76.6M
Oct 13, 2024 2 years earlier	2.57M	6	$951M
Oct 14, 2023 3 years earlier	1.20M	5	$292M
Oct 14, 2022 4 years earlier	972K	6	$211M
Oct 14, 2021 5 years earlier	2.15M	6	$350M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty12 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Medpace Holdings, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology572 filings on record, 73 filed in the 12-month period, and how we read them

All 572 Forms 3, 4 and 5 on record for Medpace Holdings, Inc. (SEC CIK 1668397), filed from Aug 10, 2016 to Oct 9, 2026; 73 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (8)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Ashley Keating	May 21, 2024	250 shares, last reported balance as of May 17, 2024
Tom King	May 24, 2022	598 shares, last reported balance as of May 20, 2022
Bruce Brown	May 21, 2019	9,295 shares, last reported balance as of May 17, 2019
Medpace Limited Partnership	Aug 27, 2018	No balance on record
Penelope Bucknell	May 4, 2017	3,000 shares, last reported balance as of May 2, 2017
Alexander Leslie		No balance on record
Matthew Norton		No balance on record
Supraj Rajagopalan		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Medpace Holdings, Inc. insiders sold $467M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Medpace Holdings, Inc. CEO selling stock?

Why are Medpace Holdings, Inc. insiders selling?

Are any Medpace Holdings, Inc. insiders buying?

The evidence

No plan disclosed · $454M

Charitable gifts · 170 shares

Sales by month